ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06498479, led by Hansoh BioMedical R&D, and recruiting on the registry. Official title: ARTEMIS-008：A Multicenter, Randomised, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy. Planned enrolment is 460 participants (estimated). The study started in 2024-07-04 and primary completion is expected in 2026-09-30. No results have been posted on ClinicalTrials.gov.